knowledge -WSS

knowledge

author：hotspot 2025-09-30 09:57:04 - browse：974

TALLINN, Estonia -- A Belarusian journalist was sentenced Friday to four years in prison after being convicted of aiding extremist activities as the authoritarian country continues a severe crackdown on the opposition and independent reporting.

The trial of video journalist Pavel Padabed was held behind closed doors. His conviction and sentencing were reported by the Belarusian Association of Journalists.

Padabed worked with Belsat, a Polish-funded satellite channel that broadcasts into Belarus and is considered by the Belarusian government to be “extremist media.”

The journalists' association said material presented at his trial included investigative programs about the disappearance of a videographer and the 2016 car bombing in Ukraine of TV journalist Pavel Sharemet.

Belarus President Alexander Lukashenko, in power since 1994, has taken an increasingly repressive line toward the opposition and independent journalists since mass protests engulfed the country in 2020 following a presidential election that gave him a sixth term in office but was widely regarded as fraudulent.

The journalists' association says 34 journalists are currently behind bars.

More than 35,000 people were arrested during the 2020 protests, and many were severely beaten by police. The Belarusian human rights group Viasna says there are nearly 1,500 political prisoners in the country.

Exiled opposition leader Sviatlana Tsikhanouskaya, who ran against Lukashenko in 2020, met Friday with European Council President Charles Michel and EU foreign policy chief Josep Borrell.

Afterward, the European Council issued a statement calling on Belarus to stop allowing Russia to base troops there for use in the war in Ukraine and end the deployment there of Russian tactical nuclear weapons.

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： FDA panel gives mixed vote on blood pressure devices

entertainment

WSS

FDA panel gives mixed vote on blood pressure devices

Amylyx ALS drug failure raises questions and concerns

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Change Healthcare cyberattack prompts Medicare loan program

Amylyx ALS drug failure raises questions and concerns

Medicare explains how it will choose drugs for negotiation

Wikipedia

knowledge

focus

Trump demands the U.S. pay no more for drugs than other countries … again

With psoriasis trial ahead, Alumis raises $259 million

New air purifier tech could be key to improving indoor air quality

Sen. Paul opposes bill to ban Chinese biotechs

Medicare details structure of new drug price negotiation program

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Tori Bowie and the unacceptable rates of Black maternal death

First medicine developed to treat MASH expected to be approved soon

Malaria cases in Florida and Texas: Here’s what you need to know

In his State of the Union, Biden takes clear aim at 'Big Pharma'

focus

UnitedHealth quietly bought dozens of outpatient centers

2024 GOP presidential candidates spar over abortion in debate

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

In science, is the line between industry and academia shifting?

With psoriasis trial ahead, Alumis raises $259 million

hotspot

entertainment

entertainment

entertainment